Skip to content

Advertisement

  • Oral presentation
  • Open Access

Preneoplasia in mouse models

  • 1
Breast Cancer Research20035 (Suppl 1) :44

https://doi.org/10.1186/bcr703

  • Published:

Keywords

  • Mammary Gland
  • Ductal Carcinoma
  • Mammary Tumor
  • Molecular Alteration
  • Mouse Mammary Tumor Virus

Premalignancy in mouse models has been studied for the past 50 years. These present as epithelial hyperplasia; several types of which occur in the mouse mammary gland depending on the initiating stimulus. Alveolar hyperplasias are frequently observed in models where mouse mammary tumor virus, hormones or chemical carcinogens are the initiating agents. Ductal hyperplasias are frequently observed in genetically engineered models where specific oncogenes have been deregulated. The premalignant nature of these lesions can be verified by transplantation into the mammary fat pads of either syngeneic or immunocompromised mice. The alveolar hyperplasias generate tumors that are frequently estrogen-receptor negative and diploid, although metastatic to lung. Estrogen receptor expression is downregulated early in premalignant progression, often when the hyperplastic lesion is first identified. The ductal hyperplasias progress through ductal carcinoma in situ and generate tumors that are frequently estrogen-receptor negative but the tumors are aneuploid. In recent years, premalignancy in genetically engineered mice has been extensively characterized at the biological level in p53 null mammary epithelium and in polyoma MT mammary gland, and to a lesser extent in the SV40LT antigen mammary gland. The molecular alterations in these lesions are beginning to be analyzed by array methodologies. These models provide the opportunity to identify early events causal in premalignant progression as well as to test the efficacy of agents that prevent progression.

Authors’ Affiliations

(1)
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA

Copyright

Advertisement